Treatments and bleeding and ischaemic events
| Total population (n=352) | Patients with major bleeding (n=19 (5.4%)) | Patients without major bleeding (n=333 (94.6%)) | p Value | |
| Treatment | ||||
| Aspirin | 350 (99.7%) | 19 (100%) | 331 (99.7%) | 1 |
| Clopidogrel (mg) | 661±267 | 609±283 | 664±267 | 0.39 |
| Abciximab | 215 (61.3%) | 10 (52.6%) | 205 (61.7%) | 0.42 |
| Unfractionated heparin only | 15 (4.3%) | 0 (0%) | 15 (4.5%) | 1 |
| LMWH only | 239 (68.1%) | 10 (52.6%) | 229 (69%) | 0.14 |
| Both unfractionated heparin and LMWH | 91 (25.9%) | 9 (47.4%) | 82 (24.7%) | 0.05 |
| Insulin | 90 (25.7%) | 5 (26.3%) | 85 (25.7%) | 1 |
| Deferred angiography | 177 (50.3%) | 12 (63.2%) | 165 (49.5%) | 0.25 |
| Immediate angiography | 175 (49.7%) | 7 (36.8%) | 168 (50.5%) | |
| Trans-radial approach | 296 (84.57%) | 13 (68.4%) | 283 (85.5%) | 0.05 |
| Femoral or humeral approach | 50 (14.29%) | 5 (26.3%) | 45 (13.6%) | |
| Multiple access | 4 (1.14%) | 1 (5.3%) | 3 (0.9%) | |
| Total length of stay | 4.9±6.5 | 13.6±9.3 | 4.4±6.0 | <0.0001 |
| Bleeding events at 1 month | ||||
| Transfusion ≥2 units | 16 (4.6%) | 16 (84.2%) | 0 (0%) | <0.0001 |
| Transfusion ≥5 units | 4 (1.1%) | 4 (21.1%) | 0 (0%) | <0.0001 |
| Ischaemic events at 1 month | ||||
| Death, myocardial infarction or urgent revascularisation | 42 (11.9%) | 5 (26.3%) | 37 (11.1%) | 0.06 |
| Death (all cause) | 7 (2%) | 5 (26.3%) | 2 (0.6%) | <0.0001 |
| Myocardial infraction | 24 (6.8%) | 2 (10.5%) | 22 (6.6%) | 0.38 |
| Urgent revascularisation | 16 (4.5%) | 1 (5.3%) | 15 (4.5%) | 0.60 |
| Recurrent ischaemia | 54 (15.3%) | 5 (26.3%) | 49 (14.7%) | 0.19 |
Values are number (%) or mean±SD.
LMWH, low molecular weight heparin.